Triamcinolone Hexacetonide and hyaluronic acid: infiltration under fluoroscopy
Triamcinolone Hexacetonide: infiltration under fluoroscopy
Study summary
For patients suffering of osteoarthritis, only analgesic treatments such as anti-inflammatory drugs and cortisone infiltrations provide significant but temporary relief of their pain. The objective is to compare the analgesic effect of 2 infiltrations: Cingal (sodium hyaluronate and triamcinolone) versus cortisone (triamcinolone). It is anticipated that the Cingal infiltration will have a greater analgesic effect than a simple cortisone infiltration in patients with moderate to severe osteoarthritis of the shoulder.
Method:
* Randomized controlled trial
* Monocentric
* Randomization will be done using sealed envelopes
Eligibility
Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* A clinical examination that confirms the radiological diagnosis of moderate to severe primary shoulder osteoarthritis, stage II and above, according to the Samilson-Prieto classification.
* Patients aged between 20 and 90 years.
* A patient with bilateral shoulder osteoarthritis will choose the side of the infiltration, only one side can be chosen to participate in the study.
* The patient must have a clinical pain threshold of a minimum of 4/10 on the visual analogue scale.
* The patient must have the cognitive ability to read and fill out the questionnaires.
* The patient must be able to read and understand French or English
Exclusion Criteria:
* Presence of a transfixing rotator cuff tear assessed on MRI.
* No previous shoulder reconstruction surgery.
* Pregnant woman.
* A patient who has received a cortisone infiltration within 6 months prior to the start of the study.
* A patient who has received a platelet-rich plasma or a hyaluronic acid infiltration within 12 months prior to the start of the study.
* Diagnosis of avascular necrosis.
* Disease affecting the studied joint (systemic inflammatory disease, history of septic arthritis, osteonecrosis, etc.)
* Suspicion or presence of active local infectious process.
* Presence or suspicion of neoplasia or local metastasis.
* Severe trauma to the shoulder ( ≤ 3 months)
* Significant cognitive impairment or insufficient language proficiency to adequately answer the questionnaires.
* Any other serious medical condition that does not allow participation in the study or may be a contraindication to cortisone injection.
Primary outcome measure(s)
Change in VAS score — Change from baseline (preinfiltration visit) VAS score at 3 months after the infiltration Visual analogue score VAS; 0-10 scale, 0: no pain 10: worst possible pain
Trial sites (1)
Facility
City
Region
Status
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal
Quebec
Recruiting
More Centre hospitalier de l'Université de Montréal (CHUM) trials in Canada
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.